Compare Toronto-Dominion Bank (TD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toronto-Dominion Bank vs BIO-TECHNE Corp — how do they compare? Toronto-Dominion Bank trades at $115.1 (market cap $185.79B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Toronto-Dominion Bank is far larger — about 16.4× BIO-TECHNE Corp's market cap, and Toronto-Dominion Bank pays the higher dividend (2.84%). Which is the better fit depends on your goals — on Pluang, investors hold Toronto-Dominion Bank for 84 Days and BIO-TECHNE Corp for 64 Days on average.
| TD | TECH | |
|---|---|---|
Market Cap | $185.79B | $11.36B |
Volume | 3,263,867 | 5,390,331 |
Sector | Financials | Health |
52-Week High | $124.80 | $72.61 |
52-Week Low | $78.32 | $43.31 |
Typical Hold Time | 84 Days | 64 Days |
Enterprise Value | $559.06B | $11.39B |
Dividend Yield | 2.84% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TD stock trades at $115.10, up 1.08% with a bearish technical signal despite strong earnings beats in recent quarters. The company maintains solid profitability with 24.88% net income margin and 13.64% ROE, supported by a $10 billion share buyback announcement. Recent news highlights expansion plans including 100 new U.S. branches and a $108 billion commitment to Canadian infrastructure.
The outlook remains positive with analyst consensus favoring Buy ratings (52.94%) and consistent earnings outperformance, though technical indicators suggest near-term pressure. Key risks include volatile cash flows and rising debt-to-asset ratios, while institutional activity shows mixed sentiment with recent insider selling.
TECH trades at $72.46, near its 52-week high of $72.70, with a slight daily decline of 0.1%. The stock shows a bullish technical signal from moving averages, while oscillators are neutral. Recent earnings have been mixed, with a Q2 2026 beat but a Q1 miss. The company maintains strong gross margins of 65.77%, though net income margin has compressed to 14.97% in 2025 from 24.6% in 2022. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The pending acquisition at $73.00 offers a clear near-term upside of about 0.7% from the current price, limiting downside risk. However, execution risks remain until deal closure, and profitability pressures pose concerns for standalone operations. Analyst consensus is divided with 46% Buy and 54% Hold ratings, reflecting cautious optimism amid transition uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
